Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Oct 11:5:64.
doi: 10.1186/1756-8722-5-64.

Novel CD20 monoclonal antibodies for lymphoma therapy

Shundong Cang  1 , Nikhil Mukhi, Kemeng Wang, Delong Liu
Affiliations
Review

Novel CD20 monoclonal antibodies for lymphoma therapy

Shundong Cang et al. J Hematol Oncol. .

Abstract

Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin's lymphoma (NHL). Novel agents are under active clinical trials. This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab), PRO131921 and GA101 (obinutumumab).

PubMed Disclaimer

Figures

Figure 1
Figure 1
The structure of CD20 molecule. Human CD20 is encoded by the gene MS4A1 gene located on chromosome 11q12.2. CD20 molecule is a 297 amino acid phosphoprotein with four transmembrane domains.
Figure 2
Figure 2
The molecular configuration of CD20 molecule. CD20 is a tetra-transmembrane protein that essentially remains on the membrane of B cells without dissociation or internalization upon antibody binding. The binding sites of CD20 monoclonal antibodies, rituximab and ofatumumab, are indicated.
See this image and copyright information in PMC

References

    1. Coiffier B. Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol. 2002;29(1 Suppl 2):30–35. - PubMed
    1. Coiffier B. Rituximab in diffuse large B-cell lymphoma. Clin Adv Hematol Oncol. 2004;2(3):156–157. - PubMed
    1. Coiffier B. Rituximab and CHOP-like chemotherapy in good-prognosis diffuse large-B-cell lymphoma. Nature clinical practice Oncology. 2006;3(11):594–595. - PubMed
    1. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26(25):3603–3613. doi: 10.1038/sj.onc.1210376. - DOI - PubMed
    1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P. et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242. doi: 10.1056/NEJMoa011795. - DOI - PubMed

MeSH terms